Cheitlin, M.D., Armstrong, W.F., Aurigemma, G.P., Beller, G.A., Bierman, F.Z., Davis, J.L., Douglas, P.S., Faxon, D.P., Gillam, L.D., Kimball, T.R., Kussmaul, W.G., Pearlman, A.S., Philbrick, J.T., Rakowski, H., Thys, D.M., Antman, E.M., Smith Jr., S.C., Alpert, J.S., Gregoratos, G., Anderson, J.L., Hiratzka, L.F., Hunt, S.A., Fuster, V., Jacobs, A.K., Gibbons, R.J., Russell, R.O., American College of Cardiology, American Heart Association and American Society of Echocardiography (2003) ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (ACC/AHA/ASE Committee to update the 1997 guidelines for the clinical application of echocardiography). Circulation, 108, 1146-1162. doi:10.1161/01.CIR.0000073597.57414.A9

has been cited by the following article:

• TITLE: Clinical follow up of patients with premature coronary artery disease (PCAD) implanted with drug-eluting stents

  AUTHORS: Xiaofeng Zhang, Yong Tang, Genshan Ma, Zhong Chen

  KEYWORDS: Coronary Artery Disease; Optimal Medicine Therapy; Percutaneous Coronary Intervention; Secondary Prevention; Major Adverse Cardiac Events

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.3 No.4, July 17, 2013

  ABSTRACT: Background: Drug-eluting stents (DESs) are associated with lower restenosis rates. However, minimal data on the follow up results of premature coronary artery disease (PCAD) treated with DESs exist. This study was to evaluate clinical characteristics and one- year prognosis of PCAD implanted with DESs in a Chinese population. Methods: 282 patients with PCAD, of which 177 implanted with DESs and 105 prescribed medicine alone were enrolled and analyzed. Major adverse cardiovascular events (MACEs) and the use of medications for secondary prevention were collected and analyzed. Results: Compared with those receiving medicine alone, patients implanted with DESs had higher ratios of males than females, they also had acute coronary syndromes, multi-vessel disease, higher values of cardiac troponin I, longer hospital stays, higher aspirin and clopidogrel use (all P β-blockers and statins use during follow-up, they had higher ratios of recurrent angina and composite MACEs during one-year follow- up (all P y syndrome (OR 1.716, 95% CI: 1.011 - 2.913) and reduced left ventricular ejection fraction (OR 2.539, 95% CI: 1.180 - 5.463) predict MACEs in a one-year follow-up among patients with PCAD. Conclusions: PCAD patients implanted with DESs have more unstable clinical phenotypes and higher MACEs during a one-year follow-up period, though they were prescribed higher ratios of optimal therapeutic medicine. Further enhanced strategies should be made for secondary prevention.